Gene therapy successfully cures two babies of cancer Gene therapy successfully cures two babies of cancer
4.5
WHY THIS MATTERS IN BRIEF New gene therapy treatments could spell the end of painful and exhausting chemotherapy treatments, and give patients new hope,... Gene therapy successfully cures two babies of cancer

WHY THIS MATTERS IN BRIEF

  • New gene therapy treatments could spell the end of painful and exhausting chemotherapy treatments, and give patients new hope, but there’s a long road ahead still


 

Just think of living in a world where people don’t have to go in for chemotherapy treatment any longer – bearing in mind that this painful and often awful procedure sometimes isn’t enough to send cancer into remission. And for those patients there are stark few alternatives. So what if there was an easier and more effective way to tackle cancer? Thanks to one recent case, there is.

 

RELATED
A cure for millions as gene therapy cures patient with Sickle Cell disease

 

Doctors at London’s Great Ormond Street Hospital (GOSH) have just announced that they’ve successfully cured two babies of Leukemia, when all other treatments had failed, and this was also the first attempt in the world to treat cancer with genetically engineered immune cells provided by a donor patient. The case is published in the journal Science Translational Medicine.

Currently, there are two methods of administering genetically engineered immune cells into a human body. The first approach, is the “off-the-shelf” approach, which was used by the doctors at GOSH. In this approach, engineered T-cells are modified to become ‘one size fits all’ for cancer patients. The patient is hooked up to an IV, and these modified cells are dripped into their veins whenever needed. The second approach involves collecting a cancer patient’s blood cells, engineering them, then dripping them back in, again through an IV.

The second approach is primarily used by companies like Juno Therapeutics and Novartis, and it costs millions of dollars and requires a huge amount of resources, so the first approach that uses universal immune cells seems more practical. However, originally, there was a lot of doubt in the field whether or not the new approach would actually work – and post op, since the babies underwent a course of chemo before the gosh doctors treated them some experts in the field have been left wondering if it was the chemo, or the new treatment, or maybe even the combination of both that cured them.

If it’s eventually demonstrated that GOSH’s new treatment did cure the infants then it could potentially save millions of lives. Doctors could collect blood from a donor, disperse it into hundreds of doses, then freeze and store it for $4,000 per dose – a much more affordable option than today’s alternative which costs over $50,000 a go. Furthermore if it is shown to be effective then it could become the defacto treatment for this horrible disease, and that in itself would be an amazing achievement.

 

RELATED
Scientists use swarms of nanobots to precisely target cancer

 

The new modified T-cells help the immune system by attacking leukemic cells, and the treatment has long been thought of as being a a theoretically simple and effective solution. Treatments that involve these engineered T-cells, like the nicknamed “off-the-shelf” approach, are known as CAR-T cell therapy, although they are not yet sold commercially. Juno Therapeutics and Novartis have previously conducted studies, finding that CAR-T cell therapy cured about half of all patients involved.

“The patient could be treated immediately, as opposed to taking cells from a patient and manufacturing them,” said Julianne Smith, vice president of CAR-T development for Cellectis, which specializes in the supply of universal cells. Still, others side with the notion that treatments should only use the patient’s own cells, not someone else’s. But whatever side of the debate you’re on it could all seem rather moot because this could be the future of alternative cancer treatments.

Matthew Griffin Global Futurist 未来学家, Tech Evangelist, XPrize Mentor ● Int'l Keynote Speaker ● Disruption, Futures and Innovation expert

Matthew Griffin, Futurist and Founder of the 311 Institute is described as “The Adviser behind the Advisers.” Among other things Matthew keeps busy helping the world’s largest smartphone manufacturers ideate the next five generations of smartphones, and what comes beyond, the world’s largest chip makers envision the next twenty years of intelligent machines, and is helping Europe’s largest energy companies re-invent energy generation, transmission and retail. Recognised in 2013, 2015 and 2016 as one of Europe’s foremost futurists, innovation and strategy experts Matthew is an award winning author, entrepreneur and international speaker who has been featured on the BBC, Discovery and other outlets. Working hand in hand with accelerators, investors, governments, multi-nationals and regulators around the world Matthew helps them envision the future and helps them transform their industries, products and go to market strategies, and shows them how the combination of new, democratised, powerful emerging technologies are helping accelerate cultural, industrial and societal change. Matthew’s clients include Accenture, Bain & Co, Bank of America, Blackrock, Booz Allen Hamilton, Boston Consulting Group, Dell EMC, Dentons, Deutsche Bank, Deloitte, Deutsche Bank, Du Pont, E&Y, Fidelity, Goldman Sachs, HPE, Huawei, JP Morgan Chase, KPMG, Lloyds Banking Group, McKinsey & Co, PWC, Qualcomm, Rolls Royce, SAP, Samsung, Schroeder’s, Sequoia Capital, Sopra Steria, UBS, the UK’s HM Treasury, the USAF and many others.

Your email address will not be published. Required fields are marked *

Translate page »

Pin It on Pinterest

Share This